Biodexa Pharmaceuticals (BDRX) Operating Leases (2018 - 2025)

Biodexa Pharmaceuticals (BDRX) has 8 years of Operating Leases data on file, last reported at $81140.1 in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 78.71% year-over-year to $81140.1; the trailing twelve-month figure through Dec 2025 stood at $81140.1 (down 78.71% YoY), and the FY2025 full-year result was $80429.1, down 78.9% from the prior year.
• Operating Leases eased to $81140.1 in Q4 2025, from $381200.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.0 million in Q4 2021 to a low of $81140.1 in Q4 2025.
• A 5-year average of $560543.6 and a median of $575894.5 in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 928.93% in 2021 and slumped 78.71% in 2025, its largest moves.
• Tracing BDRX's Operating Leases over 5 years: stood at $1.0 million in 2021, then fell by 29.12% to $731907.3 in 2022, then retreated by 21.32% to $575894.5 in 2023, then slumped by 33.81% to $381200.0 in 2024, then tumbled by 78.71% to $81140.1 in 2025.
• Business Quant data shows BDRX's Operating Leases at $81140.1 in Q4 2025, $381200.0 in Q4 2024, and $575894.5 in Q4 2023.